Meta-Analysis
Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Sep 7, 2014; 20(33): 11886-11893
Published online Sep 7, 2014. doi: 10.3748/wjg.v20.i33.11886
S-1-based vs non-S-1-based chemotherapy in advanced gastric cancer: A meta-analysis
Jian Yang, Yan Zhou, Ke Min, Qiang Yao, Chun-Ni Xu
Jian Yang, Yan Zhou, Ke Min, Qiang Yao, Chun-Ni Xu, Department of Oncology, Affiliated Yixing People’s Hospital, Jiangsu University, Wuxi 214200, Jiangsu Province, China
Author contributions: Yang J, Zhou Y and Xu CN collected and analyzed the data, wrote and revised the manuscript; Min K and Yao Q provided analytic tools and checked the accuracy of the data; Xu CN conceived, designed and supervised the study.
Correspondence to: Chun-Ni Xu, Professor, Department of Oncology, Affiliated Yixing People’s Hospital, Jiangsu University, Tongzhenguan Road No.75, Wuxi 214200, Jiangsu Province, China. staff911@yxph.com
Telephone: +86-510-87330792 Fax: +86-510-87330792
Received: February 26, 2014
Revised: April 24, 2014
Accepted: May 25, 2014
Published online: September 7, 2014
Core Tip

Core tip: This meta-analysis aimed to assess the efficacy and tolerability of S-1-based vs non-S-1-based chemotherapy in advanced gastric cancer (AGC). Compared to non-S-1-based regimens, the use of S-1-based regimens were associated with an increase in the objective response rate, overall survival, time-to-treatment failure, and a lower risk of grade 3 or 4 adverse events. S-1-based chemotherapy may be a good choice for AGC, at least in Asia because of longer survival times, better tolerance and more convenient use.